Fractyl's AAV gene therapy for type 2 diabetes enters first-in-human testing with endoscopic pancreatic delivery

The first adeno-associated virus (AAV)-based gene therapy candidate for type 2 diabetes has cleared regulatory review for human testing, as Massachusetts-based Fractyl Health (Nasdaq: GUTS) [receives authorization](https://www.globenewswire.com/news-release/2026/05/11/3291742/0/en/Fractyl-Health-Authorized-to-Initiate-First-in-Human-Trial-of-RJVA-001-in-the-Netherlands-First-Gene-Therapy-Candidate-to-Enter-Clinical-Development-for-Type-2-Diabetes.html) from Dutch regulators to initiate its Phase I/II first-in-human study of RJVA-001 in the Netherlands. The development marks a departure from the pharmacological management model that has defined type 2 diabetes treatment for decades. RJVA-001, the lead candidate from Fractyl's Rejuva gene therapy platform, is designed as a one-time intervention. Delivered via endoscopic ultrasound-guided intrapancreatic infusion, it uses a proprietary engineered version of the human insulin promoter to drive nutrient-responsive GLP-1 secretion from transduced pancreatic beta cells. The intended effect is physiologic GLP-1 expression triggered by meals, localized to the pancreas, rather than the sustained high systemic drug levels associated with injectable GLP-1 receptor agonists (GLP-1RAs). ## Trial design and RJVA-001 gene therapy diabetes study structure The [Phase I/II study](https://www.globenewswire.com/news-release/2026/05/11/3291742/0/en/Fractyl-Health-Authorized-to-Initiate-First-in-Human-Trial-of-RJVA-001-in-the-Netherlands-First-Gene-Therapy-Candidate-to-Enter-Clinical-Development-for-Type-2-Diabetes.html) is an open-label, multicenter, single-ascending-dose trial enrolling adults aged 35–70 with inadequately controlled type 2 diabetes despite stable background therapy including GLP-1RAs and up to three non-insulin oral agents. Eligible participants must have an HbA1c between 7.0% and 10.0% and a BMI of 27–40 kg/m². Prior demonstrated tolerance and benefit from GLP-1RAs is required for inclusion. The design comprises three escalating dose cohorts of three participants each, followed by an optional expansion cohort of up to 20 additional participants at the selected dose. All participants undergo a standardized medication run-in and GLP-1 washout before receiving the infusion. Follow-up extends to 12 months, with long-term monitoring for up to five years. Primary endpoints cover safety and tolerability. Secondary endpoints assess glycemic control via continuous glucose monitoring, including time-in-range. Exploratory endpoints include beta-cell function, metabolic biomarkers, cardiovascular risk markers, and transgene expression. Fractyl expects first-patient dosing and preliminary data in the second half of 2026, subject to site activation. A clinical trial application has also been submitted in Australia, with regulatory feedback expected in Q3 2026. ## Research context The rationale for a pancreas-targeted GLP-1 gene therapy in type 2 diabetes is grounded in the disease's core pathophysiology. Type 2 diabetes involves progressive beta-cell dysfunction alongside insulin resistance, and the incretin axis — particularly GLP-1 signaling — is impaired in affected individuals. Approved GLP-1RAs compensate by delivering supraphysiologic circulating drug concentrations, which restore glycemic regulation but also produce the GI side effects and adherence challenges that limit their real-world utility. RJVA-001 attempts to restore GLP-1 activity at the source, using the beta cell's own nutrient-sensing machinery to gate secretion. By placing GLP-1 expression under the control of an engineered insulin promoter, the construct is designed to activate only in response to nutrient intake, mirroring normal incretin physiology. This approach, if it functions as intended in humans, would sidestep the pharmacokinetic profile responsible for much of the side effect burden associated with systemic GLP-1 therapy. The broader gene therapy field has not previously advanced an AAV-based candidate into human trials for type 2 diabetes, and Fractyl's claim that RJVA-001 is the first such program appears consistent with the available evidence. The competitive landscape in diabetes gene therapy remains early-stage, with most activity confined to preclinical work or focused on monogenic forms of diabetes rather than the common polygenic form. Within Fractyl's own pipeline, a second Rejuva candidate, RJVA-002, targeting obesity via dual GIP/GLP-1 gene therapy, remains in preclinical development. No IND application has been filed with the US FDA for any Rejuva candidate, and the program has not received US regulatory authorization for human use. Fractyl's parallel clinical asset, Revita, a procedural therapy targeting duodenal mucosal remodeling for post-GLP-1 weight maintenance, is in pivotal development under the REMAIN-1 trial. The company states that Rejuva's clinical development is funded within its existing cash runway into early 2027, beyond the anticipated REMAIN-1 pivotal data readout, with no change to capital plans. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/aav-gene-therapy-type-2-diabetes-fractyls-for)